Centrexion Therapeutics
PrivateLast Round
Debt
Dec 14, 2023
Total Funding Raised
$252.44M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Centrexion Therapeutics is a biopharmaceutical company that develops and commercializes non-opioid and non-addictive therapies for the treatment of chronic pain.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Centrexion Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Centrexion Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Dec 14, 2023 | ||||
| Convertible Debt | Jul 11, 2023 | ||||
| Convertible Debt | Oct 29, 2020 | ||||
| Series D | Jan 2, 2018 | ||||
| Convertible Debt | Oct 10, 2017 | ||||
Convertible Debt | Apr 28, 2017 |
Centrexion Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| InterWest Partners | Series C, Convertible Debt, Series D, Series B, Series A |
| New Enterprise Associates (NEA) | Series C, Convertible Debt, Series D, Series A, Series B |
| SLR Capital Partners | Convertible Debt |
| ArrowMark Partners | Series C, Convertible Debt, Series D |
| Efung Capital | Series D |
| 6 Dimensions Capital | Series D |
| Exome Asset Management | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 18, 2026
Monthly visitors increased 140% MoM, reaching 2.9K.
- Oct 29, 2020
$41M round with participation from Eli Lilly and Company.
Centrexion Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Centrexion Therapeutics's valuation, stock price, and market status.